Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

702 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Molecular pathogenesis of IDH mutations in gliomas.
Ichimura K. Ichimura K. Brain Tumor Pathol. 2012 Jul;29(3):131-9. doi: 10.1007/s10014-012-0090-4. Epub 2012 Mar 8. Brain Tumor Pathol. 2012. PMID: 22399191 Review.
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, Collins VP. Ichimura K, et al. Neuro Oncol. 2009 Aug;11(4):341-7. doi: 10.1215/15228517-2009-025. Epub 2009 May 12. Neuro Oncol. 2009. PMID: 19435942 Free PMC article.
Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses.
Vogazianou AP, Chan R, Bäcklund LM, Pearson DM, Liu L, Langford CF, Gregory SG, Collins VP, Ichimura K. Vogazianou AP, et al. Among authors: ichimura k. Neuro Oncol. 2010 Jul;12(7):664-78. doi: 10.1093/neuonc/nop075. Epub 2010 Feb 17. Neuro Oncol. 2010. PMID: 20164239 Free PMC article.
MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.
Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Bäcklund LM, Collins VP, Ichimura K. Mulholland S, et al. Among authors: ichimura k. Int J Cancer. 2012 Sep 1;131(5):1104-13. doi: 10.1002/ijc.26499. Epub 2012 Jan 11. Int J Cancer. 2012. PMID: 22020830
Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
Ohno M, Narita Y, Miyakita Y, Okita Y, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Kayama T, Shibui S. Ohno M, et al. Among authors: ichimura k. Brain Tumor Pathol. 2012 Oct;29(4):183-91. doi: 10.1007/s10014-012-0113-1. Epub 2012 Jul 13. Brain Tumor Pathol. 2012. PMID: 22790483
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.
Okita Y, Narita Y, Miyakita Y, Ohno M, Matsushita Y, Fukushima S, Sumi M, Ichimura K, Kayama T, Shibui S. Okita Y, et al. Among authors: ichimura k. Int J Oncol. 2012 Oct;41(4):1325-36. doi: 10.3892/ijo.2012.1564. Epub 2012 Jul 20. Int J Oncol. 2012. PMID: 22825915
Molecular markers in pediatric neuro-oncology.
Ichimura K, Nishikawa R, Matsutani M. Ichimura K, et al. Neuro Oncol. 2012 Sep;14 Suppl 4(Suppl 4):iv90-9. doi: 10.1093/neuonc/nos204. Neuro Oncol. 2012. PMID: 23095836 Free PMC article. Review.
A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy.
Fukushima S, Narita Y, Miyakita Y, Ohno M, Takizawa T, Takusagawa Y, Mori M, Ichimura K, Tsuda H, Shibui S. Fukushima S, et al. Among authors: ichimura k. Neuropathology. 2013 Oct;33(5):576-81. doi: 10.1111/neup.12022. Epub 2013 Feb 13. Neuropathology. 2013. PMID: 23406431
Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas.
Ohno M, Narita Y, Miyakita Y, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Shibui S. Ohno M, et al. Among authors: ichimura k. Brain Tumor Pathol. 2013 Oct;30(4):224-32. doi: 10.1007/s10014-013-0140-6. Epub 2013 Mar 14. Brain Tumor Pathol. 2013. PMID: 23494632
Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K. Arita H, et al. Among authors: ichimura k. Acta Neuropathol. 2013 Aug;126(2):267-76. doi: 10.1007/s00401-013-1141-6. Epub 2013 Jun 14. Acta Neuropathol. 2013. PMID: 23764841
702 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback